| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Sprague-Dawley (CD, Crl (SD)Br) rats of both sexes were dosed with 3, 5, or 900 mg/kg of Methylene 14C-Labeled FMC 57020 (2[(2'-chlorophenyl)-14C-methyl]-4,4-dimethyl-3-isoxazolidinone; radiopurity: 99.8%; specific activity: 26.81 mCi/mmol). In Study A, two rats/sex were orally dosed by gavage with 5 mg/kg of the test material and expired air was collected for up to 24 hours. In the remaining studies, 5 animals/sex/group were dosed. In Studies B and C, the animals received a single oral dose of 5 and 900 mg/kg of the test material, respectively. In Study D, each animal was dosed intravenously with 3 mg/kg of the test material. In Study E, the animals received 14 doses, once per day for 2 weeks, of unlabeled FMC 57020 (purity: 99.0%). In Study B, C, D and E, urine and feces samples were collected periodically for 7 days. After 7 days, the animals were euthanized and radioactivity in the tissues was determined. Excretion of radiolabeled CO2 constituted less than 0.01% of the recovered dose. The primary pathway of excretion was in the urine with a range of 63.4 to 82.9% of the administered dose in the urine. Recovery in the feces ranged from 15.1 to 38.7% of the administered dose. At 7 days post-dose, aggregate residue levels in the tissues and carcass ranged from 0.08 to 0.17% of the administered dose. The amount dosed or frequency of the dosing did not affect the excretory profile. Metabolism / Metabolites Four Sprague-Dawley rats/sex were treated by oral gavage with a single dose of 50 mg/kg of a mixture of Methylene-14C FMC 57020 (specific activity: 26.85 mCi/mmol, radiochemical purity: 99.3%) and Carbonyl-14C FMC 57020 (specific activity: 27.98 mCi/mmol, radiochemical purity: 99.3%). Radiolabeled compounds were recovered from the urine and feces samples and analyzed... in order to identify various metabolites of the test material. Twelve metabolites were recovered and identified. Hydroxylation of the phenyl and/or isoxazolidinone rings was the most common alteration of the parent compound which was observed with some evidence of glucuronide and sulfate conjugation. |
|---|---|
| Toxicity/Toxicokinetics |
Toxicity Summary
Clomazone induces oxidative stress and AChE inhibition in human erythrocytes (in vitro), suggesting a role for reactive oxygen species in the toxicity mechanism induced by clomazone in humans. (A15208) Toxicity Data LC50 (rat) = 4,800 mg/m3/4h Non-Human Toxicity Values LD50 Rat oral 1369 mg/kg (female) LD50 Rat oral 2077 mg/kg (male) LD50 Rabbit dermal >2000 mg/kg LC50 Rat inhalation 4.8 mg/L/4 hr |
| References | |
| Additional Infomation |
Clomazone is an isoxazolidinone that is 1,2-oxazolidin-3-one substituted by a 2-chlorobenzyl group at position 2 and two methyl groups at position 4. It has a role as an environmental contaminant, a xenobiotic, a herbicide, an agrochemical and a carotenoid biosynthesis inhibitor. It is a member of monochlorobenzenes and an isoxazolidinone.
Clomazone, a white solid compound, is an agricultural herbicide, and has been the active ingredient of products named. The molecule consists of a 2-chlorobenzyl group bound to a N-O heterocycle called Isoxazole. |
| Molecular Formula |
C12H14CLNO2
|
|---|---|
| Molecular Weight |
239.699
|
| Exact Mass |
239.071
|
| CAS # |
81777-89-1
|
| PubChem CID |
54778
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
317.6±44.0 °C at 760 mmHg
|
| Melting Point |
25°C
|
| Flash Point |
145.9±28.4 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.551
|
| LogP |
2.17
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
16
|
| Complexity |
280
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
KIEDNEWSYUYDSN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H14ClNO2/c1-12(2)8-16-14(11(12)15)7-9-5-3-4-6-10(9)13/h3-6H,7-8H2,1-2H3
|
| Chemical Name |
2-[(2-chlorophenyl)methyl]-4,4-dimethyl-1,2-oxazolidin-3-one
|
| Synonyms |
Clomazone FMC 57020 Dimethazone Magister Command Gamit
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~417.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.43 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.43 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.43 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1719 mL | 20.8594 mL | 41.7188 mL | |
| 5 mM | 0.8344 mL | 4.1719 mL | 8.3438 mL | |
| 10 mM | 0.4172 mL | 2.0859 mL | 4.1719 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
